AU2002212962A1 - Use of tolterodine to treat asthma - Google Patents

Use of tolterodine to treat asthma

Info

Publication number
AU2002212962A1
AU2002212962A1 AU2002212962A AU1296202A AU2002212962A1 AU 2002212962 A1 AU2002212962 A1 AU 2002212962A1 AU 2002212962 A AU2002212962 A AU 2002212962A AU 1296202 A AU1296202 A AU 1296202A AU 2002212962 A1 AU2002212962 A1 AU 2002212962A1
Authority
AU
Australia
Prior art keywords
treatment according
asthma
effective amount
tolterodine
allergic rhinitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212962A
Other languages
English (en)
Inventor
Sue K. Cammarata
Per-Goran Gillberg
Staffan Sundquist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia AB
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB, Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia AB
Publication of AU2002212962A1 publication Critical patent/AU2002212962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
AU2002212962A 2000-10-24 2001-10-23 Use of tolterodine to treat asthma Abandoned AU2002212962A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24289900P 2000-10-24 2000-10-24
US60242899 2000-10-24
US28312001P 2001-04-11 2001-04-11
US60283120 2001-04-11
US31421801P 2001-08-22 2001-08-22
US60314218 2001-08-22
PCT/US2001/027779 WO2002034245A2 (en) 2000-10-24 2001-10-23 Use of tolterodine to treat asthma

Publications (1)

Publication Number Publication Date
AU2002212962A1 true AU2002212962A1 (en) 2002-05-06

Family

ID=27399612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212962A Abandoned AU2002212962A1 (en) 2000-10-24 2001-10-23 Use of tolterodine to treat asthma

Country Status (9)

Country Link
US (1) US6538035B2 (es)
EP (1) EP1330241A2 (es)
JP (1) JP2004513099A (es)
AR (1) AR031032A1 (es)
AU (1) AU2002212962A1 (es)
CA (1) CA2422901A1 (es)
MX (1) MXPA03003592A (es)
PE (1) PE20020547A1 (es)
WO (1) WO2002034245A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
JP3981357B2 (ja) * 2001-10-26 2007-09-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 第４級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
CA2475374A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
BRPI0409370A (pt) * 2003-04-15 2006-04-25 Pharmacia & Upjohn Co Llc compostos de amÈnio quaternário e seus usos como agentes antimuscarìnicos
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
ES2268987B1 (es) 2005-08-05 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de 3,3-difenilpropilaminas.
EA016203B1 (ru) 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
JP2010539154A (ja) * 2007-09-14 2010-12-16 ファイザー・リミテッド ムスカリン様受容体アンタゴニストとして活性な新規化合物
KR101188333B1 (ko) 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
IL128096A0 (en) 1996-07-29 1999-11-30 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters their use pharmaceutical compositions and preparation
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재

Also Published As

Publication number Publication date
CA2422901A1 (en) 2002-05-02
MXPA03003592A (es) 2003-06-19
JP2004513099A (ja) 2004-04-30
WO2002034245A2 (en) 2002-05-02
PE20020547A1 (es) 2002-06-12
US20020161054A1 (en) 2002-10-31
AR031032A1 (es) 2003-09-03
EP1330241A2 (en) 2003-07-30
US6538035B2 (en) 2003-03-25

Similar Documents

Publication Publication Date Title
US8450339B2 (en) Compositions for treatment of common cold
US6538035B2 (en) Use of tolterodine to treat asthma
WO2019157099A1 (en) Intranasal epinephrine formulations and methods for the treatment of disease
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
CA2540174A1 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
EP1496882B1 (en) Tolterodine salts
US9119777B2 (en) Methods and compositions for administration of oxybutynin
JP2006506345A5 (es)
JP5492072B2 (ja) 喘息の増悪の予防および／または治療のためのフォルモテロールおよびジプロピオン酸ベクロメタゾンを含む組成物の使用
CN101983060A (zh) 治疗呼吸系统疾病的方法和组合物
ES2291618T3 (es) Composicion farmaceutica a base de un agente inhibidor de la pde4 o de la pde3/4 y de un agente antagonista de receptores de histamina.
WO2006030221A1 (en) Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
US20120101076A1 (en) Carbonate derivatives for the treatment of cough
AU2019217643B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
WO2021064589A1 (en) Intranasal pharmaceutical compositions of cyclobenzaprine
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
JP2015533131A (ja) 咳を治療するためのベータ２−アドレナリン受容体作動薬
CN1713902A (zh) 包含罗氟司特和(r,r)－福莫特罗的协同组合物
WO2004016590A1 (fr) Sels de derives de quinuclidine, elaboration et applications
AU2002329578B2 (en) Compositions for treatment of common cold
CN111643672A (zh) 包含胆碱水杨酸和去氧肾上腺素的液体组合物及其制备方法和用途
AU2002329578A1 (en) Compositions for treatment of common cold
WO2005041969A1 (en) Pharmaceutical product comprising a beta-2 adrenergic agonist and an h1-receptor antagonist